Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Evolus Inc
(NQ:
EOLS
)
11.77
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Evolus Inc
< Previous
1
2
3
4
5
6
Next >
Evolus to Report Second Quarter 2023 Results and Provide Business Update
July 19, 2023
From
Evolus
Via
Business Wire
Twitter Faces Threats From AI and Threads
July 15, 2023
AI is changing the open internet landscape, and Meta's new Threads app is looking to take a bite out of Twitter's audience.
Via
The Motley Fool
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
June 29, 2023
From
Evolus
Via
Business Wire
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
June 22, 2023
From
Evolus
Via
Business Wire
Expert Ratings for Evolus
May 26, 2023
Via
Benzinga
This Analyst Likes Evolus As 'Top Play In Aesthetics'
May 10, 2023
Evolus Inc (NASDAQ: EOLS) will be the exclusive U.S.
Via
Benzinga
Expert Ratings for Evolus
May 10, 2023
Via
Benzinga
Evolus: Q1 Earnings Insights
May 09, 2023
Via
Benzinga
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
June 08, 2023
From
Evolus
Via
Business Wire
Evolus Reports First Quarter 2023 Results and Provides Business Update
May 09, 2023
From
Evolus
Via
Business Wire
Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese
May 09, 2023
From
Evolus, Inc.
Via
Business Wire
Evolus Earnings Preview
May 08, 2023
Via
Benzinga
Analyst Expectations for Evolus's Future
March 09, 2023
Via
Benzinga
Preview: Evolus's Earnings
March 07, 2023
Via
Benzinga
Evolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown Lines
January 30, 2023
Via
Benzinga
Evolus to Report First Quarter 2023 Results and Provide Business Update
May 05, 2023
From
Evolus, Inc.
Via
Business Wire
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
March 08, 2023
From
Evolus
Via
Business Wire
Evolus to Participate in the Barclays Global Healthcare Conference
February 28, 2023
From
Evolus
Via
Business Wire
Evolus Initiates Nuceiva® Launch in Germany and Austria
February 27, 2023
From
Evolus, Inc.
Via
Business Wire
Earnings Scheduled For March 8, 2023
March 08, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.
Via
Benzinga
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
February 22, 2023
From
Evolus
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
February 20, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
February 17, 2023
Via
Benzinga
Evolus Not Affected by Recent Korean Court Ruling
February 10, 2023
From
Evolus
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 10, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 07, 2023
Via
Benzinga
Evolus to Participate in the SVB Securities Global Biopharma Conference
January 31, 2023
From
Evolus
Via
Business Wire
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
January 28, 2023
From
Evolus
Via
Business Wire
Evolus Receives Regulatory Approval for Nuceiva® in Australia
January 23, 2023
From
Evolus
Via
Business Wire
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
January 23, 2023
From
Evolus
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.